253 related articles for article (PubMed ID: 22655678)
1. Clear cell carcinoma of the ovary: is there a role of histology-specific treatment?
Takano M; Tsuda H; Sugiyama T
J Exp Clin Cancer Res; 2012 Jun; 31(1):53. PubMed ID: 22655678
[TBL] [Abstract][Full Text] [Related]
2. Less impact of adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study.
Takano M; Sugiyama T; Yaegashi N; Sagae S; Kuzuya K; Udagawa Y; Tsuda H; Suzuki M; Kigawa J; Goto T; Tsuda H; Moriya T; Kikuchi Y
Int J Gynecol Cancer; 2010 Dec; 20(9):1506-10. PubMed ID: 21119366
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage I ovarian clear cell carcinoma.
Ho CM; Chien TY; Shih BY; Huang SH
Gynecol Oncol; 2003 Mar; 88(3):394-9. PubMed ID: 12648592
[TBL] [Abstract][Full Text] [Related]
4. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease.
Ho CM; Huang YJ; Chen TC; Huang SH; Liu FS; Chang Chien CC; Yu MH; Mao TL; Wang TY; Hsieh CY
Gynecol Oncol; 2004 Jul; 94(1):197-203. PubMed ID: 15262142
[TBL] [Abstract][Full Text] [Related]
5. The impact of complete surgical staging upon survival in early-stage ovarian clear cell carcinoma: a multi-institutional retrospective study.
Takano M; Sugiyama T; Yaegashi N; Suzuki M; Tsuda H; Sagae S; Udagawa Y; Kuzuya K; Kigawa J; Takeuchi S; Tsuda H; Moriya T; Kikuchi Y
Int J Gynecol Cancer; 2009 Nov; 19(8):1353-7. PubMed ID: 20009889
[TBL] [Abstract][Full Text] [Related]
6. Impact of surgical staging in stage I clear cell adenocarcinoma of the ovary.
Suzuki K; Takakura S; Saito M; Morikawa A; Suzuki J; Takahashi K; Nagata C; Yanaihara N; Tanabe H; Okamoto A
Int J Gynecol Cancer; 2014 Sep; 24(7):1181-9. PubMed ID: 25010038
[TBL] [Abstract][Full Text] [Related]
7. Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study.
Takano M; Sugiyama T; Yaegashi N; Sakuma M; Suzuki M; Saga Y; Kuzuya K; Kigawa J; Shimada M; Tsuda H; Moriya T; Yoshizaki A; Kita T; Kikuchi Y
Int J Gynecol Cancer; 2008; 18(5):937-42. PubMed ID: 18081792
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary.
Takano M; Kikuchi Y; Yaegashi N; Suzuki M; Tsuda H; Sagae S; Udagawa Y; Kuzuya K; Kigawa J; Takeuchi S; Tsuda H; Moriya T; Sugiyama T
Oncol Rep; 2006 Dec; 16(6):1301-6. PubMed ID: 17089053
[TBL] [Abstract][Full Text] [Related]
9. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease.
Goff BA; Sainz de la Cuesta R; Muntz HG; Fleischhacker D; Ek M; Rice LW; Nikrui N; Tamimi HK; Cain JM; Greer BE; Fuller AF
Gynecol Oncol; 1996 Mar; 60(3):412-7. PubMed ID: 8774649
[TBL] [Abstract][Full Text] [Related]
10. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
Li M; Li H; Liu F; Bi R; Tu X; Chen L; Ye S; Cheng X
J Ovarian Res; 2017 Feb; 10(1):9. PubMed ID: 28187748
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: an analysis of fully staged patients.
Takada T; Iwase H; Iitsuka C; Nomura H; Sakamoto K; Omatsu K; Takeshima N; Takizawa K
Int J Gynecol Cancer; 2012 May; 22(4):573-8. PubMed ID: 22398705
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study.
Takakura S; Takano M; Takahashi F; Saito T; Aoki D; Inaba N; Noda K; Sugiyama T; Ochiai K;
Int J Gynecol Cancer; 2010 Feb; 20(2):240-7. PubMed ID: 20169667
[TBL] [Abstract][Full Text] [Related]
13. Survival impact of adjuvant paclitaxel and carboplatin for early-stage ovarian clear-cell carcinoma with complete surgical staging.
Kajiyama H; Shibata K; Suzuki S; Ino K; Kawai M; Nagasaka T; Nawa A; Kikkawa F
Gynecol Obstet Invest; 2011; 72(4):252-6. PubMed ID: 22041903
[TBL] [Abstract][Full Text] [Related]
14. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
[TBL] [Abstract][Full Text] [Related]
15. Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis.
Takano M; Sugiyama T; Yaegashi N; Suzuki M; Tsuda H; Sagae S; Udagawa Y; Kuzuya K; Kigawa J; Takeuchi S; Tsuda H; Moriya T; Kikuchi Y
Int J Clin Oncol; 2007 Aug; 12(4):256-60. PubMed ID: 17701003
[TBL] [Abstract][Full Text] [Related]
16. The post-progression survival of patients with recurrent or persistent ovarian clear cell carcinoma: results from a randomized phase III study in JGOG3017/GCIG.
Kondo E; Tabata T; Suzuki N; Aoki D; Yahata H; Kotera Y; Tokuyama O; Fujiwara K; Kimura E; Terauchi F; Sumi T; Okamoto A; Yaegashi N; Enomoto T; Sugiyama T
J Gynecol Oncol; 2020 Nov; 31(6):e94. PubMed ID: 33078599
[TBL] [Abstract][Full Text] [Related]
17. Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial.
Sugiyama T; Okamoto A; Enomoto T; Hamano T; Aotani E; Terao Y; Suzuki N; Mikami M; Yaegashi N; Kato K; Yoshikawa H; Yokoyama Y; Tanabe H; Nishino K; Nomura H; Kim JW; Kim BG; Pignata S; Alexandre J; Green J; Isonishi S; Terauchi F; Fujiwara K; Aoki D
J Clin Oncol; 2016 Aug; 34(24):2881-7. PubMed ID: 27400948
[TBL] [Abstract][Full Text] [Related]
18. Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary.
Itamochi H; Kigawa J; Sugiyama T; Kikuchi Y; Suzuki M; Terakawa N
Obstet Gynecol; 2002 Aug; 100(2):281-7. PubMed ID: 12151151
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy.
Sugiyama T; Kamura T; Kigawa J; Terakawa N; Kikuchi Y; Kita T; Suzuki M; Sato I; Taguchi K
Cancer; 2000 Jun; 88(11):2584-9. PubMed ID: 10861437
[TBL] [Abstract][Full Text] [Related]
20. Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging.
Takano M; Kikuchi Y; Yaegashi N; Kuzuya K; Ueki M; Tsuda H; Suzuki M; Kigawa J; Takeuchi S; Tsuda H; Moriya T; Sugiyama T
Br J Cancer; 2006 May; 94(10):1369-74. PubMed ID: 16641903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
